Testagen
A synthetic tetrapeptide (Lys-Glu-Asp-Gly) from the Khavinson bioregulator family, studied for testicular tissue bioregulation and age-related hormonal support.
Also referenced as: KEDG, Lys-Glu-Asp-Gly
Also appears in: Longevity
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Other. Also surfaces under Longevity for browsing and discovery.
KEDG, Lys-Glu-Asp-Gly
No FDA label signal · 1 trials · 13 PubMed results
Testagen has human trials registered, but none have reported controlled results yet. Most current claims about what it does in people rest on preclinical (lab or animal) work, not published human data.
Testagen has 1 name-matched clinical trial (highest phase: Phase 2) and 13 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is Testagen?
Testagen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Gly (KEDG), developed as part of the Khavinson bioregulator peptide program. It is classified as a testicular-tissue bioregulator, theorized to support age-related testicular function through tissue-specific gene modulation.
How it works
- Peptide-DNA interaction — short peptides are proposed to penetrate cell nuclei and interact with gene promoter regions, modulating transcription in a tissue-specific manner (Khavinson et al., Bulletin of Experimental Biology and Medicine, 2011)
- Hormonal support — Testagen is theorized to support endogenous testosterone-related pathways in aging testicular tissue, though specific gene targets have not been identified in Western peer-reviewed literature
Research status
- Khavinson (2005) reviewed the broader peptide bioregulator program (Gerontology, 51(2):70–75)
- Anisimov et al. (2003) reported geroprotective effects of bioregulator peptide preparations in rodent models (Annals of the New York Academy of Sciences, 992:141–147)
- No specific Western peer-reviewed clinical trials for Testagen have been published
Key considerations
- Part of the Khavinson bioregulator family — same proposed mechanism as Prostamax, Pinealon, Cartalax, and others
- Research originates from a single group with limited independent replication
- Available from research vendors as lyophilized powder or capsules (typically 10–20mg)
- Not to be confused with pharmaceutical testosterone replacement therapies